U.S. Pharmaceutical CDMO Market Size, Share, and Trends 2024 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID-19 Impact on U.S. Pharmaceutical CDMO Market 

5.1. COVID-19 Landscape: U.S. Pharmaceutical CDMO Industry Impact

5.2. COVID-19  Impact Assessment for the Industry

5.3. COVID-19 Impact:  Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Pharmaceutical CDMO Market, By Service Type

8.1. U.S. Pharmaceutical CDMO Market, by Service Type, 2024-2034

8.1.1. Active Pharmaceutical Ingredient (API) Manufacturing

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Finished Dosage Formulation (FDF) Development and Manufacturing

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Liquid Dose Formulation

8.1.3.1. Market Revenue and Forecast (2021-2034)

8.1.4. Injectable Dose Formulation

8.1.4.1. Market Revenue and Forecast (2021-2034)

8.1.5. Secondary Packaging

8.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 9. U.S. Pharmaceutical CDMO Market, By Research Phase

9.1. U.S. Pharmaceutical CDMO Market, by Research Phase, 2024-2034

9.1.1. Pre-Clinical

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Phase I

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Phase II

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Phase III

9.1.4.1. Market Revenue and Forecast (2021-2034)

9.1.5. Phase IV

9.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 10. U.S. Pharmaceutical CDMO Market, U.S. Estimates and Trend Forecast

10.1. U.S.

10.1.1. Market Revenue and Forecast, by Service Type (2021-2034)

10.1.2. Market Revenue and Forecast, by Research Phase (2021-2034)

Chapter 11. Company Profiles

11.1. Thermo Fisher Scientific Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Laboratory Corporation of America Holdings

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Catalent, Inc

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Cambrex Corporation

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms